Supplement Table3 Biological pathways that associated with the hypermethylated genes in the AML(a) and CRC cases(b) from the TCGA database

a

Term / Pathway Names / P-Value
hsa04270 / Vascular smooth muscle contraction / 0.0002
hsa04912 / GnRH signaling pathway / 0.0009
hsa00565 / Ether lipid metabolism / 0.0027
hsa04730 / Long-term depression / 0.003
hsa04664 / Fc epsilon RI signaling pathway / 0.0067
hsa04370 / VEGF signaling pathway / 0.0177
hsa00592 / alpha-Linolenic acid metabolism / 0.02
hsa05414 / Dilated cardiomyopathy / 0.0246
hsa00640 / Propanoate metabolism / 0.0297
hsa05210 / Colorectal cancer / 0.0308
hsa05410 / Hypertrophic cardiomyopathy (HCM) / 0.0348
hsa05213 / Endometrial cancer / 0.0399
hsa00903 / Limonene and pinene degradation / 0.0677
hsa00591 / Linoleic acid metabolism / 0.0794
hsa05221 / Acute myeloid leukemia / 0.0888
hsa05412 / Arrhythmogenic right ventricular cardiomyopathy (ARVC) / 0.116
hsa00410 / beta-Alanine metabolism / 0.1444
hsa00830 / Retinol metabolism / 0.1737
hsa04672 / Intestinal immune network for IgA production / 0.1783
hsa00650 / Butanoate metabolism / 0.1911
hsa00590 / Arachidonic acid metabolism / 0.2086
hsa05215 / Prostate cancer / 0.2129
hsa04660 / T cell receptor signaling pathway / 0.2457
hsa04940 / Type I diabetes mellitus / 0.2534
hsa04662 / B cell receptor signaling pathway / 0.2542
hsa05416 / Viral myocarditis / 0.2826
hsa00280 / Valine, leucine and isoleucine degradation / 0.3013
hsa00053 / Ascorbate and aldarate metabolism / 0.3083
hsa05310 / Asthma / 0.3475
hsa05330 / Allograft rejection / 0.3888
hsa05218 / Melanoma / 0.3964
hsa04650 / Natural killer cell mediated cytotoxicity / 0.4502
hsa00860 / Porphyrin and chlorophyll metabolism / 0.4747
hsa05332 / Graft-versus-host disease / 0.4761
hsa00980 / Metabolism of xenobiotics by cytochrome P450 / 0.5486
hsa00040 / Pentose and glucuronate interconversions / 0.5947
hsa05320 / Autoimmune thyroid disease / 0.6283
hsa00983 / Drug metabolism / 0.7414
hsa00140 / Steroid hormone biosynthesis / 0.7989
hsa04260 / Cardiac muscle contraction / 0.8561
hsa00150 / Androgen and estrogen metabolism / 0.8845
hsa04612 / Antigen processing and presentation / 0.9027
hsa04621 / NOD-like receptor signaling pathway / 0.9583
hsa04620 / Toll-like receptor signaling pathway / 0.9608
hsa04622 / RIG-I-like receptor signaling pathway / 0.9629

b

Term / Pathway Names / P-Value
hsa05218 / Melanoma / 0.0056
hsa04930 / Type II diabetes mellitus / 0.045
hsa04960 / Aldosterone-regulated sodium reabsorption / 0.076
hsa05223 / Non-small cell lung cancer / 0.0786
hsa05214 / Glioma / 0.1378
hsa05210 / Colorectal cancer / 0.1875
hsa04012 / ErbB signaling pathway / 0.2113
hsa05215 / Prostate cancer / 0.2277
hsa05412 / Arrhythmogenic right ventricular cardiomyopathy (ARVC) / 0.2495
hsa04666 / Fc gamma R-mediated phagocytosis / 0.2795
hsa05222 / Small cell lung cancer / 0.3279
hsa05213 / Endometrial cancer / 0.3305
hsa05414 / Dilated cardiomyopathy / 0.4091
hsa04150 / mTOR signaling pathway / 0.5621
hsa05212 / Pancreatic cancer / 0.5778
hsa04062 / Chemokine signaling pathway / 0.6044
hsa05220 / Chronic myeloid leukemia / 0.6105
hsa04662 / B cell receptor signaling pathway / 0.6105
hsa05221 / Acute myeloid leukemia / 0.637
hsa05410 / Hypertrophic cardiomyopathy (HCM) / 0.7077
hsa04660 / T cell receptor signaling pathway / 0.7298
hsa04910 / Insulin signaling pathway / 0.7744
hsa04664 / Fc epsilon RI signaling pathway / 0.82
hsa04260 / Cardiac muscle contraction / 0.82
hsa04370 / VEGF signaling pathway / 0.9284
hsa04650 / Natural killer cell mediated cytotoxicity / 0.9453

2